Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics

European Neuropsychopharmacology

Volumn 10, Issue 2, 2000, Pages 119-124

  Maes, Michael ^a,b,c,d   Bocchio Chiavetto, Luisella ^a   Bignotti, Stefano ^a   Battisa Tura, Giani Jean ^a   Pioli, Rosaria ^a   Boin, Francesco ^a   Kenis, Gunter ^e   Bosmans, Eugene ^e   De Jongh, Raf ^f   Lin, Aihua ^b   Racagni, Giorgio ^a,g   Altamura, C A ^a,h  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^b Clinical Research Center for Mental Health of Antwerp   (Belgium)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d VANDERBILT UNIVERSITY   (United States)

^e Eurogenetics   (Belgium)

^f General Hospital St Jan   (Belgium)

^g Department of Pharmacology   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

Author keywords

CC16; Clozapine; Cytokines; Interleukin 6; Schizophrenia; Treatment resistance

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CELL PROTEIN; CLARA CELL PROTEIN; CLORAZEPATE DIPOTASSIUM; CLOZAPINE; HALOPERIDOL; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LORAZEPAM; NEUROLEPTIC AGENT; PERPHENAZINE; RISPERIDONE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESISTANCE; HUMAN; INFLAMMATION; PRIORITY JOURNAL; SCHIZOPHRENIA; STATISTICAL ANALYSIS;

EID: 17744415696     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0924-977x(99)00062-0     Document Type: Article

References (41)

1. Altamura, C., Maes, M., 1999. Editorial: hypercortisolemia, schizophrenia and atypical antipsychotics. Eur. Neuropsychopharmacol. (in press).
2. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition :1994;APA, Washington, DC.
3. Arolt V., Weitzsch C., Wilke I., Nolte A., Pinnow M., Rothermundt M., Kirchner H. Production of interferon-gamma in families with multiple occurrence of schizophrenia. Psychiatr. Res. 66:(2-3):1997;145-152.
4. Baker I., Masserano J., Wyatt R.J. Serum cytokine concentrations in patients with schizophrenia. Schizophr. Res. 20:1996;199-203.
5. Chengappa K.N., Ganguli R., Yang Z.W., Shurin G., Brar J.S., Rabin B.S. Impaired mitogen (PHA) responsiveness and increased autoantibodies in Caucasian schizophrenic patients with the HLA B8/DR3 phenotype. Biol. Psychiatry. 37:1995;546-549.
6. Dayer J.-M., Burger D. Interleukin-1, tumor necrosis factor and their specific inhibitors. Eur. Cytokine Netw. 5:1994;563-571.
7. DeLisi L.E., Crow T.J. Is schizophrenia a viral or immunological disorder? Psychiatr. Clin. North Am. 9:1986;115-132.
8. DeLisi L.E., King A.C., Targum S. Serum immunoglobulin concentrations in patients admitted to an acute psychiatric in-patient service. Br. J. Psychiatry. 145:1985;661-665.
9. Dierynck I., Bernard A., Roels H., De Ley M. Potent inhibition of both interferon-γ production and biologic activity by the Clara cell protein CC16. Am. J. Respir. Cell. Mol. Biol. 12:1995;205-210.
10. Frommberger U.H., Bauer J., Haselbauer P., Fraulin A., Riemann D., Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur. Arch. Psychiatr. Clin. Neurosci. 247:1997;228-233.
11. Ganguli R., Rabin B.S. Increased serum interleukin-2 receptor concentration in schizophrenic and brain damaged subjects. Arch. Gen. Psychiatry. 46:1989;292.
12. Ganguli R., Brar J.S., Solomon W., Chengappa K.N.R., Rabin B.S. Altered interleukin-2 production in schizophrenia: association between clinical state and autoantibody production. Psychiatr. Res. 44:1992;113-123.
13. Ganguli R., Yang Z., Shurin G., Chengappa K.N.R., Brar J.S., Gubbi A.V., Rabin B.S. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatr. Res. 51:1994;1-10.
14. Kane J., Honigfeld G., Singer J., Meltzer H.Y. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 45:1988;789-796.
15. Katila H., Appelberg B., Hurme M., Rimon R. Plasma levels of interleukin-1β and interleukin-6 in schizophrenia, other psychoses, and affective disorders. Schizophr. Res. 12:1994;29-34.
16. Kirch D.G. Infection and autoimmunity as etiologic factors in schizophrenia: a review and reappraisal. Schizophr. Bull. 19:1993;355-370.
17. Leykin I., Mayer R., Shinitzky M. Short and long term immunosuppressive effects of clozapine and haloperidol. Immunopharmacology. 37:1997;75-86.
18. Licinio J., Krystal J.H., Seibyl J.P., Altemus M., Charney D.S. Elevated central levels of interleukin-2 in drug-free schizophrenic patients. Schizophr. Res. 44:1991;372.
19. Lin A., Kenis G., Bignotti S., Tura G.J., De Jong R., Bosmans E., Pioli R., Altamura C., Scharpé S., Maes M. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr. Res. 32:1998;9-15.
20. Maes M., Scharpe S., Meltzer H.Y., Bosmans E., Suy E., Minner B., Calabrese J., Uyttenbroeck W., Vandervorst C., Raus J., Cosyns P. Relationship between interleukin-6 activity, acute phase proteins and HPA-axis function in severe depression. Psychiatr. Res. 49:1993;11-27.
21. Maes M., Meltzer H.Y., Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr. Scand. 89:1994;346-351.
22. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatr. Res. 29:1995;141-152.
23. Maes M., Bosmans E., Ranjan R., Vandoolaeghe E., Meltzer H.Y., DeLey M., Bergmans R., Stans G., Desnyder R. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1-receptor-antagonist in schizophrenia. Schizophr. Res. 21:1996;39-50.
24. Maes M., Bosmans E., Kenis G., De Jong R., Smith R.S., Meltzer H.Y. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr. Res. 26:1997;221-225.
25. Maes M., Delanghe J., Ranjan R., Meltzer H.Y., Desnyder R., Cooreman W., Scharpe S. The acute phase protein response in schizophrenia, mania and major depression: effects of psychotropic drugs. Psychiatr. Res. 66:1997;1-11.
26. Maes M., Song C., Lin A., de Jongh R., Van Gastel A., Kenis G., Bosmans E., De Meester I., Benoy I., Neels H., Demedts P., Janca A., Scharpe S., Smith R.S. The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine. 10:1998;313-318.
27. Maes M., Song C., Lin A., De Jongh R., Van Gastel A., Kenis G., Bosmans E., De Meester I., Neels H., Janca A., Scharpe S., Smith R.S. Immune and clinical correlates of psychological stress-induced production of interferon-γ and IL-10 in humans. Plotnikoff N.P., Faith R.E., Murgo A.J., Good R.A. Cytokines, Stress and Immunity. 1998;39-50 CRC Press, Boca-Raton, FL.
28. Miele L., Cordella-Miele E., Mukherjee A.B. Uteroglobin: structure, molecular biology, and new perspectives on its function as a phospholipase A2 inhibitor. Endocr. Rev. 8:1987;474-490.
29. Monteleone P., Fabrazzo M., Tortorella A., Maj M. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatr. Res. 71:1997;11-17.
30. Muller N., Hofschuster E., Ackenheil M., Eckstein R. T-cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy. Acta Psychiatr. Scand. 87:1993;66-71.
31. Muller N., Empl M., Riedel M., Schwarz M., Ackenheil M. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur. Arch. Psychiatr. Clin. Neurosci. 247:1997;308-313.
32. Naudin J., Mege J.L., Azorin J.M., Dassa D. Elevated circulating levels of IL-6 in schizophrenia. Schizophr. Res. 20:1996;269-273.
33. Pollmacher T., Hinze-Selch D., Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J. Clin. Psychopharmacol. 16:1996;403-409.
34. Rapaport M.H., McAllister C.G., Pickar D., Nelson D.L., Paul S.M. Elevated levels of soluble interleukin-2 receptors in schizophrenia. Arch. Gen. Psychiatry. 46:1989;291-292.
35. Rhoades H.M., Overall J.E. The semistructured BPRS interview and rating guide. Psychopharmacol. Bull. 10:1988;101-104.
36. Rothermundt M., Arolt V., Weitzsch C., Eckhoff D., Kirchner H. Immunological dysfunction in schizophrenia: a systematic approach. Neuropsychobiology. 37:1998;186-193.
37. Singh G., Katyal S.L. An immunological study of the secretory products of rat Clara cells. J. Histochem. Cytochem. 32:1984;49-54.
38. Sirota P., Schild K., Elizur A., Djaldetti M., Fishman P. Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry. 19:1995;75-83.
39. Smith R., Maes M. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med. Hypoth. 45:1995;135-141.
40. Suzuki E., Shintani F., Kanba S., Asai M., Nakaki T. Induction of interleukin-1 beta and interleukin-1 receptor antagonist mRNA by chronic treatment with various psychotropics in widespread area of rat brain. Neurosci. Lett. 215:1996;201-204.
41. Wilke I., Arolt V., Rothermundt M., Weitzsch C., Hornberg M., Kirchner H. Investigation of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur. Arch. Psychiatr. Clin. Neurosci. 246:1996;279-284.